Advertisement

Drugs & Therapy Perspectives

, Volume 21, Issue 4, pp 10–13 | Cite as

Gonadotropins and gonadotropin-releasing hormone analogues are vital parts of pharmacological manipulation in assisted reproduction

Disease Management

References

  1. 1.
    Huirne JAF, Lambalk CB, van Loenen ACD, et al. Contemporary pharmacological manipulation in assisted reproduction. Drugs 2004; 64(3): 297–322PubMedCrossRefGoogle Scholar
  2. 2.
    Eijkemans MJ, Imani B, Mulders AG, et al. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003; 18: 2357–62PubMedCrossRefGoogle Scholar
  3. 3.
    Van Santbrmk EJ, Fauser BC. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 1997; 82(11): 3597–602CrossRefGoogle Scholar
  4. 4.
    Van Santbrmk EJ, Donderwinkel PF, van Dessel TJ, et al. Gona-dotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 1995; 10(5): 1048–53Google Scholar
  5. 5.
    Griesinger G, Felberbaum RE, Schultze-Mosgau A, et al. Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents? Drugs 2004; 64(6): 563–75PubMedCrossRefGoogle Scholar
  6. 6.
    British national formulary. No. 48. London: The Pharmaceutical Press, 2004 SepGoogle Scholar
  7. 7.
    Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone vs human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev. 2000; (2): CD000087PubMedGoogle Scholar
  8. 8.
    Coelingh Bennink HJ, Fauser BC, Out HJ. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. Fertil Steril 1998; 69(1): 19–25CrossRefGoogle Scholar
  9. 9.
    Bayram N, Van Wely M, Van der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2001; (2): CD002121PubMedGoogle Scholar
  10. 10.
    Macklon NS, Fauser BC. Alternative approaches to ovarian stimulation for IVF. Reprod Med Rev 2001; 9: 77–89CrossRefGoogle Scholar
  11. 11.
    Schipper I, Hop WC, Fauser BC. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development. J Clin Endocrinol Metab 1998; 83(4): 1292–8PubMedCrossRefGoogle Scholar
  12. 12.
    Hohmann FP, Laven JS, de Jong FH, et al. Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development. Hum Reprod 2001; 16(5): 846–54PubMedCrossRefGoogle Scholar
  13. 13.
    Hohmann FP, Macklon NS, Fauser BCJM. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003; 88(1): 166–73PubMedCrossRefGoogle Scholar
  14. 14.
    Harlin J, Aanesen A, Csemiczky G, et al. Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation. Hum Reprod 2002; 17(2): 304–9PubMedCrossRefGoogle Scholar
  15. 15.
    Burgues S. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod 2001; 16(12): 2525–32PubMedCrossRefGoogle Scholar
  16. 16.
    The European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001; 86(6): 2607–18CrossRefGoogle Scholar
  17. 17.
    Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996; 11(5): 917–9PubMedCrossRefGoogle Scholar
  18. 18.
    Janssens RM, Lambalk CB, Vermeiden JP, et al. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000; 15(11): 2333–40PubMedCrossRefGoogle Scholar
  19. 19.
    Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev. 2000; (2): CD001299PubMedGoogle Scholar
  20. 20.
    AL-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17(4): 874–85PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations